In conclusion, our study revealed that SGLT2 inhibitors regulate sympathetic activity by increasing COMT activity associated with the correction of hypomagnesemia and may be involved in preventing liver fibrosis by inhibiting IL-6 production in KCs. Here, IL6 is linked to familial primary hypomagnesemia.